Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Gandhi S, Zelman S, De Armas RE, Hemond C, Levy AN, Singh S, Korzenik J, Jangi S. Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis. Inflamm Bowel Dis. 2022 10 03; 28(10):1614-1617.
-
Henning L, Antony H, Breuer A, M?ller J, Seifert G, Audinat E, Singh P, Brosseron F, Heneka MT, Steinh?user C, Bedner P. Reactive microglia are the major source of tumor necrosis factor alpha and contribute to astrocyte dysfunction and acute seizures in experimental temporal lobe epilepsy. Glia. 2023 Feb; 71(2):168-186.
-
Baker JF, Reed G, Poudel DR, Harrold LR, Kremer JM. Obesity and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022 11; 74(11):1909-1916.
-
Feinberg PA, Becker SC, Chung L, Ferrari L, Stellwagen D, Anaclet C, Dur?n-Laforet V, Faust TE, Sumbria RK, Schafer DP. Elevated TNF-a Leads to Neural Circuit Instability in the Absence of Interferon Regulatory Factor 8. J Neurosci. 2022 08 10; 42(32):6171-6185.
-
Crabtree JN, Caffrey DR, de Souza Silva L, Kurt-Jones EA, Dobbs K, Dent A, Fitzgerald KA, Golenbock DT. Lymphocyte crosstalk is required for monocyte-intrinsic trained immunity to Plasmodium falciparum. J Clin Invest. 2022 06 01; 132(11).
-
Kerur B, Fiedler K, Stahl M, Hyams J, Stephens M, Lu Y, Pfefferkorn M, Alkhouri R, Strople J, Kelsen J, Siebold L, Goyal A, Rosh JR, LeLeiko N, Van Limbergen J, Guerrerio AL, Maltz RM, Karam L, Crowley E, Griffiths AM, Heyman MB, Deneau M, Benkov K, Noe J, Moulton D, Pappa H, Galanko J, Snapper S, Muise AM, Kappelman MD, Benchimol EI. Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America. J Pediatr Gastroenterol Nutr. 2022 07 01; 75(1):64-69.
-
Sharma A, Raman V, Lee J, Forbes NS. Microbial Imbalance Induces Inflammation by Promoting Salmonella Penetration through the Mucosal Barrier. ACS Infect Dis. 2022 05 13; 8(5):969-981.
-
Kwan Cheung KA, Abeysinghe P, Vaswani K, Tucker K, Bassett J, Mitchell PA, Mosaad EMO, Logan J, Mitchell MD. Characterisation of ReNcells CX and VM stimulated with interleukin-1? and lipopolysaccharide. Neurochem Int. 2022 06; 156:105326.
-
Chun N, Ang RL, Chan M, Fairchild RL, Baldwin WM, Horwitz JK, Gelles JD, Chipuk JE, Kelliher MA, Pavlov VI, Li Y, Homann D, Heeger PS, Ting AT. T cell-derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death. JCI Insight. 2021 12 22; 6(24).
-
Kr?mer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-Garc?a R, Schulte-Schrepping J, Kaiser KM, Rieke GJ, Bischoff J, Monin MB, Hoffmeister C, Schlabe S, De Domenico E, Reusch N, H?ndler K, Reynolds G, Bl?thgen N, Hack G, Finnemann C, Nischalke HD, Strassburg CP, Stephenson E, Su Y, Gardner L, Yuan D, Chen D, Goldman J, Rosenstiel P, Schmidt SV, Latz E, Hrusovsky K, Ball AJ, Johnson JM, Koenig PA, Schmidt FI, Haniffa M, Heath JR, K?mmerer BM, Keitel V, Jensen B, Stubbemann P, Kurth F, Sander LE, Sawitzki B, Aschenbrenner AC, Schultze JL, Nattermann J. Early IFN-a signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021 11 09; 54(11):2650-2669.e14.